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Abstract 
Background: Serious mental illnesses are associated with increased risk of cardiometabolic comorbidities. The objec‑
tive of this study was to evaluate the prevalence of cardiometabolic comorbidity and its association with hospitaliza‑
tion outcomes and costs among inpatients with schizophrenia or bipolar disorder.
Methods: This retrospective database analysis reviewed patients with an inpatient diagnosis of schizophrenia or 
bipolar disorder from the Premier Perspective® Database (4/1/2010–6/30/2012). Patients were categorized into 4 
cohorts based on the number of ICD‑9‑CM cardiometabolic comorbidities (i.e., 0, 1, 2, or 3+). Outcomes included 
length of stay, mortality during the index hospitalization, healthcare costs, and 30‑day all‑cause readmission rates.
Results: Of 57,506 patients with schizophrenia, 66.1% had at least one cardiometabolic comorbidity; 39.3% had two 
or more comorbidities. Of 124,803 patients with bipolar disorder, 60.5% had at least one cardiometabolic comorbid‑
ity; 33.4% had two or more. Average length of stay was 8.5 (for patients with schizophrenia) and 5.2 (for patients with 
bipolar disorder) days. Each additional cardiometabolic comorbidity was associated with an increase in length of stay 
for patients with bipolar disorder (p < .001) but not for patients with schizophrenia. Mortality rates during the index 
hospitalization were 1.2% (schizophrenia) and .7% (bipolar disorder). Each additional cardiometabolic comorbidity was 
associated with a significant increase in mortality for patients with bipolar disorder (OR 1.218, p < .001), and a numeri‑
cal increase in mortality for patients with schizophrenia (OR 1.014, p = .727). Patients with more cardiometabolic 
comorbidities were more likely to have a 30‑day readmission (schizophrenia = 9–13%; bipolar disorder = 7–12%), and 
to incur higher costs (schizophrenia = $10,606–15,355; bipolar disorder = $7126–13,523) (all p < .01).
Conclusions: Over 60% of inpatients with schizophrenia or bipolar disorder had cardiometabolic comorbidities. 
Greater cardiometabolic comorbidity burden was associated with an increased likelihood of readmission and higher 
costs among patients with schizophrenia or bipolar disorder, and an increase in length of stay and mortality for 
patients with bipolar disorder.
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Background
Severe and persistent mental illnesses that are often 
debilitating to patients, such as schizophrenia and bipo-
lar disorder, are associated with increased physical 
comorbidities and mortality [1–7]. Schizophrenia is 
characterized by psychosis, behavioral dysfunction, and 
cognitive impairment and has a prevalence of approxi-
mately 1% in the United States (US) [8]. Bipolar disorder 
is a mood disorder characterized by intermittent periods 
of mania and major depression that has an approximate 
lifetime prevalence of 4% among adults in the US [9]. The 
severe psychiatric symptoms and accompanying func-
tional disability among patients that suffer from these 
Open Access
Annals of General Psychiatry
*Correspondence:  daisy.ng‑mak@sunovion.com 
3 Sunovion Pharmaceuticals Inc., 84 Waterford Dr., Marlborough, MA 
01752, USA
Full list of author information is available at the end of the article
Page 2 of 8Correll et al. Ann Gen Psychiatry  (2017) 16:9 
debilitating disorders often result in high rates of unem-
ployment [10], incarceration [11], and suicide [12].
Compounding the psychiatric disability in schizophre-
nia and bipolar disorder, a growing literature suggests 
that physical comorbidities in this population reduce 
life expectancy by as much as 10–25  years and double 
the risk of premature mortality compared to the gen-
eral population [7]. Patients with schizophrenia have 2.4 
times the rate of metabolic syndrome and 2.0 times the 
rate of diabetes than the general population [1]. Similarly, 
patients with bipolar disorder have 2.0 times the rate of 
metabolic syndrome [2] and 1.7 times the rate of diabe-
tes [3] than the general population. Furthermore, some 
evidence suggests that the prevalence of cardiometabolic 
risks is underestimated among patients with schizophre-
nia [4, 5] or bipolar disorder [9] due to under-diagnosis 
and under-treatment.
Complicating the inherent higher risk of cardiometa-
bolic comorbidities in patients with schizophrenia or 
bipolar disorder, atypical antipsychotics, which are 
standard pharmacological treatment for schizophrenia 
and many patients with bipolar disorder, can exacerbate 
patients’ risk of cardiometabolic disease [13]. For exam-
ple, treatment with certain atypical antipsychotics is 
associated with an increasing risk of developing meta-
bolic syndrome [14, 15], diabetes [16–19], and elevated 
low-density lipoprotein cholesterol levels [19–21].
Hospital readmissions within 30  days post-hospital 
discharges (i.e., 30-day readmissions) have become an 
important measure of health care quality due to the high 
30-day readmission rates among US Medicare benefi-
ciaries [22]. Evidence suggests that 30-day readmissions 
are a significant predictor of long-term mortality [23]. 
In order to reduce 30-day readmission rates, the Cent-
ers for Medicare and Medicaid Services implemented 
the Medicare Hospital Readmissions Reduction Program 
which, as a penalty, reduces Medicare payments to hospi-
tals with excess 30-day readmissions relative to the mean 
national readmission rates in conditions such as acute 
myocardial infarction and heart failure [24]. In a statis-
tical brief summarizing the readmission trend in 2013, 
schizophrenia, mood disorder, and diabetes were among 
the top 20 conditions with the highest all-cause 30-day 
readmission rates [25].
While the prevalence, outcomes, and costs of car-
diometabolic comorbidities in patients with schizo-
phrenia and bipolar disorder have been examined in 
some outpatient studies [1–3], these variables remain 
relatively unexplored in hospitalized patients. In addi-
tion, although there is extensive literature regarding 
30-day readmissions attributed to particular illnesses 
such as mental (e.g., schizophrenia) or cardiometa-
bolic conditions (e.g., diabetes), the incremental impact 
of cardiometabolic conditions on readmission among 
patients with schizophrenia or bipolar disorder remains 
unknown. Therefore, the objectives of this study were to 
determine the prevalence of cardiometabolic comorbidi-
ties among inpatients with schizophrenia and bipolar 
disorder and to assess the role of incremental cardio-
metabolic comorbidity burden on length of stay, mortal-
ity, and healthcare costs during the initial admission. 
Following discharge, the study also examined the role of 




This retrospective observational study used administra-
tive hospital data from the Premier Perspective Data-
base® (Premier, Inc., Charlotte, NC, USA) during the 
period from April 1, 2010 to June 30, 2012. The Premier 
database is the largest hospital administrative database in 
the US and provides detailed service information from 
over 700 geographically dispersed hospitals and over 50 
million discharges since 2000. The database contained 
detailed service level information, diagnostic informa-
tion, hospital characteristics, and patient demographic 
information. The database did not include any identifi-
able protected health information and, pursuant to the 
Health Insurance Portability and Accountability Act of 
1996 [26], the study did not require institutional review 
board waiver or approval.
Patient selection
Patients with a primary, secondary, or admitting diagno-
sis of schizophrenia (International Classification of Dis-
eases, 9th Revision, Clinical Modification [ICD-9-CM] 
code 295.xx) or bipolar disorder (ICD-9-CM codes 296.0, 
296.1, 296.4–296.8, 301.11, or 301.13) coded during their 
hospitalization stays were identified between October 
1, 2010 and May 31, 2012. The first such hospitalization 
record was designated as the patient’s index hospitali-
zation. Patients diagnosed with both schizophrenia and 
bipolar disorder, patients who were less than 18-year old, 
or patients who were transferred from another hospital 
or an unknown admission source were excluded from the 
analysis.
Variable definitions
Six cardiometabolic comorbidities were examined for 
both the patients with schizophrenia and bipolar disor-
der: cerebrovascular disease (ICD-9-CM 430–438.xx), 
coronary or ischemic heart disease (ICD-9-CM 410.
xx–411.xx, 413.xx–414.xx), diabetes mellitus (ICD-9-CM 
250.xx), hyperglycemia (ICD-9-CM 790.2), hyperlipi-
demia (ICD-9-CM 272.x), and hypertension (ICD-9-CM 
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401.x–405.x). Patients were categorized into 1 of 4 
comorbidity cohorts based on the number of cardiomet-
abolic comorbidity diagnoses recorded during their index 
hospitalization (i.e., 0, 1, 2, or 3+). In addition to exam-
ining these specific cardiometabolic comorbidities, the 
Charlson Comorbidity Index (CCI) was coded based on 
an algorithm developed for administrative data [27] using 
comorbidities reported during the index hospitalization 
as well as all inpatient or outpatient hospitalizations in 
the Premier database that occurred in 6 months prior to 
the index admission.
Outcome variables
Outcome variables during the index hospitalization 
included length of stay, mortality, and costs. Following 
discharge from the index hospitalization, 30-day all-
cause readmission rates were also examined. Length of 
stay in days and mortality were obtained from the dis-
charge record for the index hospitalization. The hospi-
tals reported both the charges for each individual service 
based on their charge master and the costs the hospital 
reported incurring to deliver the services. This analy-
sis focused on the costs to deliver services, which were 
split into pharmacy and medical costs with the medi-
cal costs representing all non-pharmacy costs. All costs 
were adjusted to 2014 US dollars using the medical care 
component of the Consumer Price Index from the US 
Bureau of Labor Statistics [28]. The 30-day all-cause 
readmission rates were defined as a subsequent readmis-
sion to the same hospital for any reason within 30 days 
of discharge.
Statistical analyses
Patient demographic and baseline characteristics were 
summarized using descriptive statistics. The relation-
ship between cardiometabolic comorbidities and study 
outcomes were evaluated using multivariate statistical 
models controlling for the following baseline variables: 
age, gender, race, payer, CCI, hospital region (Midwest, 
Northeast, South, and West), hospital location (urban/
rural), hospital type (teaching/non-teaching), and hospi-
tal bed count. For the dichotomous outcome variables, 
mortality and 30-day readmission, logistic regression 
models were used. Length of stay was treated as count 
data and a negative binomial regression was used. Finally, 
for the highly skewed cost variables, total costs, phar-
macy costs, and medical costs, generalized linear models 
(GLMs) with a gamma distribution and log-link function 
were used. The statistical models were fit separately for 
the schizophrenia and bipolar samples. Statistical analy-
ses were conducted using SAS version 9.4 (SAS Institute, 




There were 118,065 patients with an inpatient hospitali-
zation for schizophrenia. Of these, 51.3% (n  =  60,559) 
were excluded for the following reasons: index hospital-
ization did not have the required 6-month prior obser-
vation or 1-month follow-up period; age younger than 
18 years; transfer from another hospital or an unknown 
admission source; diagnoses of both schizophrenia 
and bipolar disorder. Among 229,974 patients with an 
inpatient hospitalization for bipolar disorder, 45.7% 
(n = 105,171) were excluded after applying the exclusion 
criteria as above. The final study sample included 57,506 
and 124,803 inpatients with a diagnosis of schizophrenia 
and bipolar disorder, respectively.
Patient characteristics
Patient characteristics are described in Table  1. The 
average age of patients with schizophrenia and bipolar 
disorder was in the mid to late 40s. The most common 
cardiometabolic comorbidities were hypertension (52% 
bipolar disorder; 57% schizophrenia), hyperlipidemia 
(28% bipolar disorder; 30% schizophrenia), and dia-
betes (22% bipolar disorder; 28% schizophrenia), with 
each numerically higher for patients with schizophrenia 
than patients with bipolar disorder. Nearly two-thirds of 
patients with schizophrenia (66.1%) and bipolar disorder 
(60.5%) had at least one cardiometabolic comorbidity, 
and over one-third of patients with schizophrenia (39.3%) 
and bipolar disorder (33.4%) had 2 or more cardiometa-
bolic comorbidities.
Outcomes
For the index hospitalization, the mean length of stay 
was 8.5 days for patients with schizophrenia and 5.2 days 
for patients with bipolar disorder. Multivariate analyses 
showed a negative association between cardiometabolic 
comorbidity burden with length of stay for schizophrenia 
(p < .001), but a positive association for bipolar disorder 
(p < .001) (see Fig. 1a).
The index hospitalization mortality rate was 1.2% for 
the patients with schizophrenia and .7% for the patients 
with bipolar disorder. For those with schizophrenia, the 
risk of death during the index hospitalization was not 
significantly associated with each additional cardiometa-
bolic comorbidity (odds ratio [OR] 1.014; 95% confidence 
interval [CI] .937, 1.098, p  =  .727). Prior to correcting 
for baseline differences, a Chi square test showed that 
patients with schizophrenia who had one or more car-
diometabolic comorbidities had a higher risk of mortal-
ity compared to those with no comorbidities (1.7 vs. .3%, 
p < .001). For those with bipolar disorder, the risk of death 
during the index hospitalization increased by 21.8% (OR 
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1.218; 95% CI 1.129, 1.314, p < .001) with each additional 
cardiometabolic comorbidity (Fig.  1c). Prior to correct-
ing for baseline differences, a Chi square test showed that 
patients with bipolar disorder who had one or more car-
diometabolic comorbidities had a higher risk of mortality 
compared to those with no comorbidities (1.45 vs. .10%, 
p < .001).
Table 1 Demographic, clinical, and  hospital facility char-







Age, years (mean) 49.8 45.4
Female (%) 43.0 63.0
Race (%)
 African American 29.0 10.0
 Caucasian 51.0 73.0
 Hispanic 2.0 1.0
 Other 18.0 15.0
Region (%)
 Midwest 24.0 24.0
 Northeast 23.0 20.0
 South 36.0 41.0
 West 17.0 15.0
Payer (%)
 Medicaid 30.0 25.0
 Medicare 51.0 35.0
 Commercial/private 9.0 24.0
 Self‑pay 6.0 9.0
 Other 5.0 6.0
Comorbidities





 Diabetes 28.0 22.0
 Hyperglycemia 2.0 2.0
 Hypertension 57.0 52.0
 Hyperlipidemia 30.0 28.0
 Ischemic heart disease 9.0 9.0
 Cerebrovascular disease 4.0 3.0
Number of cardiometabolic comorbidities (%)
 0 33.9 39.5
 1 26.7 27.1
 2 19.9 16.6
 3+ 19.4 16.8
Hospital characteristics
Bed size (mean) 436 409
Urban (%) 89.0 86.0
Teaching (%) 48.0 42.0
Fig. 1 Length of stay, 30‑day all‑cause readmission, and hospital 
mortality by number of cardiometabolic comorbidities. a The mean 
length of stay was 8.5 days for overall patients with schizophrenia 
and 5.2 days for patients with bipolar disorder. Negative binomial 
regressions showed a negative association between cardiometabolic 
comorbidity burden with length of stay for schizophrenia (−.015; 
95% CI −.024, −.007, p < .001), but a positive association for bipolar 
disorder (.029; 95% CI .024, .034, p < .001). b Overall, 11.8% of the 
patients with schizophrenia and 9.3% of the patients with bipolar 
disorder were readmitted for any reason within 30 days of discharge 
from the index hospitalization. For each additional cardiometabolic 
comorbidity, logistic regressions showed the odds of readmis‑
sion increased by 3.1% (OR 1.031; 95% CI 1.001, 1.061, p = .042) for 
schizophrenia and by 6.4% (OR 1.064; 95% CI 1.041, 1.087, p < .001) for 
bipolar disorder. c The index hospitalization mortality rate was 1.2% 
for overall patients with schizophrenia and .7% for patients with bipo‑
lar disorder. In schizophrenia, cardiometabolic comorbidity was not 
significantly associated with mortality (OR 1.014; 95% CI .937, 1.098, 
p = .727). A Chi square test showed that patients with schizophrenia 
who had one or more cardiometabolic comorbidities had a higher 
risk of mortality compared to those with no comorbidities (1.7 vs. .3%, 
p < .001). In bipolar disorder, each additional cardiometabolic comor‑
bidity was associated with a 21.8% increase in mortality during the 
index hospitalization (OR 1.218; 95% CI 1.129, 1.314, p < .001). A Chi 
square test showed that patients with bipolar disorder who had one 
or more cardiometabolic comorbidities had a higher risk of mortality 
compared to those with no comorbidities (1.45 vs. .10%, p < .001).  
* The following covariates were included in all regression analyses: 
age, gender, race, payer, CCI, hospital region, hospital location (urban/
rural), hospital type (teaching/non‑teaching), and hospital bed count
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 Hospitalization costs increased as the number of car-
diometabolic comorbidities increased (see Fig.  2). For 
patients with schizophrenia, the mean total cost for the 
index hospitalization was $12,781 per patient (medical 
and pharmacy costs of $11,771 and $1010 per patient, 
respectively). Medical costs increased by 6.8%, pharmacy 
costs by 25.9%, and total costs by 8.3% (all p  <  .0001) 
for each additional cardiometabolic comorbidity. For 
patients with bipolar disorder, the mean total cost for the 
index hospitalization was $9725 per patient (medical and 
pharmacy costs of $8878 and $847 per patient, respec-
tively). Medical costs increased by 12.3%, pharmacy costs 
by 26.6%, and total costs by 13.4% (all p < .0001) for each 
additional cardiometabolic comorbidity.
Within 30-days of discharge from the index hospitaliza-
tion, 11.8% of the patients with schizophrenia and 9.3% of 
the patients with bipolar disorder were readmitted for any 
reason. Odds of readmission increased by 3.1% (OR 1.031; 
95% confidence interval [CI] 1.001, 1.061, p  =  .042) for 
patients with schizophrenia and by 6.4% (OR 1.064; 95% CI 
1.041, 1.087, p < .001) for patients with bipolar disorder (see 
Fig. 1b) with each additional cardiometabolic comorbidity.
Discussion
In this large, nationally representative administrative 
database study of hospitalized patients with schizophre-
nia and bipolar disorder, cardiometabolic comorbidities 
were common. Over 60% of patients had ≥1 cardiometa-
bolic comorbidity and over 30% had ≥2 cardiometabolic 
comorbidities. Increasing cardiometabolic comorbidity 
burden was associated with a significantly higher mor-
tality rate (for bipolar disorder), and longer hospital 
stays (for bipolar disorder). Patients with schizophrenia 
appeared to have almost double the rates of mortality in 
comparison to patients with bipolar disorder. The aver-
age total all-cause hospitalization cost was $12,781 and 
$9725 per patient for schizophrenia and bipolar disorder, 
respectively. Each incremental cardiometabolic comor-
bidity was associated with an 8.3 and 13.4% increase in 
total hospital cost for patients with schizophrenia and 
bipolar disorder, respectively. While 1 in 10 schizophre-
nia or bipolar disorder patients had an all-cause readmis-
sion within 30-days after index hospitalization, the odds 
of 30-day readmission increased with each incremental 
cardiometabolic comorbidity.
The reported frequencies of cardiometabolic comor-
bidities in this study are generally consistent with those 
previously reported in the literature [1, 2, 15, 29, 30]. 
However, this study identified a higher prevalence of dia-
betes in patients with schizophrenia and bipolar disor-
der (28 and 22%, respectively) than previously reported 
(7–15%) [4, 6, 30–33]. This discrepancy in the reported 
prevalence of diabetes may be due to the study popula-
tion; previous studies have typically been drawn from 
Fig. 2 Medical, pharmacy, and total costs by number of cardiometabolic comorbidities. Dollar figures reflect the costs to the hospital to deliver 
care in 2014 dollars. For both schizophrenia and bipolar disorder, increasing cardiometabolic comorbidity was associated with increased pharmacy, 
medical, and total index hospitalization costs (all p < .001). The following covariates were included in the gamma regression analyses with a log link: 
age, gender, race, payer, CCI, hospital region, hospital location (urban/rural), hospital type (teaching/non‑teaching), and hospital bed count. * The 
data are presented by number of cardiometabolic comorbidities. Overall mean total cost for patients with schizophrenia was $12,781 per patient 
(medical and pharmacy costs of $11,771 and $1010 per patient, respectively). Overall mean total cost for patients with bipolar disorder was $9725 
per patient (medical and pharmacy costs of $8878 and $847 per patient, respectively)
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broader health system populations [30], clinical trial 
participants [4], or primary care settings [6]. Among the 
general population, nearly 20% of hospital stays in the US 
are associated with diabetes [34]. The prevalence of dia-
betes found among inpatients with schizophrenia (28%) 
or bipolar disorder (22%) in this study is therefore plau-
sible, given that they are already considered a high-risk 
population for diabetes [33].
To the best of our knowledge, this is the first study to 
evaluate the risk of 30-day readmission among hospital-
ized patients with schizophrenia or bipolar disorder and 
its association with incremental cardiometabolic comor-
bidity burden. Our study showed that incremental cardi-
ometabolic comorbidity burden was associated with a 3.1 
and 6.4% increased risk of early readmission in patients 
with schizophrenia and bipolar disorder, respectively. A 
recent chart review study of 945 patients hospitalized in 
a psychiatric care facility found that psychiatric readmis-
sion in the following year was independently predicted by 
higher body mass index (BMI) [35]. The authors hypoth-
esized that inflammation, which has been associated with 
both higher BMI and obesity as well as psychiatric disor-
ders [36] may represent the link between the greater BMI 
and need for readmission, but research examining the 
mechanisms of early readmissions and cardiometabolic 
comorbidities is needed.
For patients with bipolar disorder, additional cardio-
metabolic comorbidity burden was associated with an 
increase in the length of stay (4.6 days for no comorbidities 
to 5.9 days for 3+ comorbidities). Surprisingly, increasing 
cardiometabolic comorbidity burden was associated with 
a small decrease in the length of stay among patients with 
schizophrenia (8.6 days for no comorbidities to 7.9 days for 
3+ comorbidities). While the reasons for these differences 
in length of stay are not known, it is possible that bipolar 
disorder patients may have been more likely to receive 
medical assessment and/or intervention for comorbid 
conditions than were patients with schizophrenia in this 
study; alternatively it is possible that patients with schiz-
ophrenia were more likely to have medical comorbidities 
that were well established and known to treatment staff 
compared to patients with bipolar disorder.
Prior research has clearly established a link between 
cardiometabolic conditions and mortality in the gen-
eral population [37]. The lack of statistical significance 
between the odds of mortality and cardiometabolic 
comorbidity burden in schizophrenia after correct-
ing for demographic and hospital characteristics was 
unexpected; however, a univariate analysis showed a 
significant association with comorbidity burden and 
mortality. Given the small sample sizes and the rarity 
of mortality incidence in this dataset, it is also plausi-
ble that the potential association between mortality and 
cardiovascular comorbidity is underestimated. Cardio-
vascular disease, along with cancer and suicide, has also 
been established as one of the leading causes of death for 
patients with schizophrenia [38]. Although information 
about the cause of death was unavailable, confounding 
of the results by suicide is likely small, as all the patients 
were hospitalized at community hospitals and not psy-
chiatric hospitals, indicating severity of a medical, rather 
than psychiatric condition at the time of admission.
Previous studies have reported increased outpatient 
or total costs for psychiatric patients with cardiometa-
bolic comorbidities [39–41]. This study is unique in that 
it demonstrated the possible relationship between each 
additional cardiometabolic comorbidity and incremental 
costs per admission for patients with schizophrenia or 
bipolar disorder.
The results of this study highlight the importance of 
identifying optimal treatment regimens for patients with 
serious mental illness. Efforts should be taken to ade-
quately monitor for and reduce the rates of cardiometa-
bolic comorbidities in this vulnerable patient population, 
and perhaps consider antipsychotic therapeutic options 
with a limited liability for such comorbidities [13]. From 
a holistic approach of treating patients with serious men-
tal illness, clinicians should coordinate care and consider 
a patients’ medical profile when prescribing medications. 
Coordinated care can also improve quality of care and 
patient satisfaction [42], which may have a positive effect 
on reducing healthcare costs through shorter hospital stays 
and/or reduced early readmissions. Furthermore, improved 
physical health may also positively impact psychiatric 
health outcomes [35]. In 2013, four new measures of the 
Healthcare Effectiveness Data and Information Set were 
added to assess quality of care for patients with serious 
mental illness; two of these four measures focus on diabe-
tes monitoring and cardiovascular monitoring, which high-
lights the importance of monitoring cardiometabolic risks 
among this susceptible patient population [43]. Monitoring 
patients’ cardiometabolic profiles, consideration of these 
risk factors when selecting antipsychotic drug therapies, 
and striving to coordinate care delivery for both mental and 
physical symptoms may maximize patients’ outcomes.
Limitations
The data used in this study were collected for adminis-
trative reasons rather than for research purposes. The 
study design precludes any determination of causal rela-
tionship between cardiometabolic comorbidities and the 
outcomes. The analysis was restricted to variables pre-
sent in this particular database, and other factors that 
were not available in the database may have confounded 
the observed relationships. Information about the prior 
treatments for the mental and physical morbidities, prior 
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hospitalizations, and reasons for death was unavailable. 
In particular, data on atypical antipsychotic utilization 
prior to hospitalization were not available, therefore it 
was not possible to assess the relationship between spe-
cific antipsychotic medications and cardiometabolic 
comorbidities, which have been previously described to 
vary substantially [2, 13, 20, 33].
The burden of cardiometabolic comorbidities in this 
study was measured using diagnostic ICD-9-CM codes 
of 6 disease entities. Studies that have used the more 
robust National Cholesterol Education Program’s Adult 
Treatment Panel III report (ATP III) or International 
Diabetes Federation (IDF) definitions [15] have reported 
metabolic syndrome prevalence of approximately 33% for 
schizophrenia [15] and 37% for bipolar disorder [2]. The 
ICD-9-CM coding did not allow for the clear identifica-
tion of bipolar II disorder (falls under “bipolar other”), 
precluding the assessment of differences in the number 
of cardiovascular comorbidities and outcomes between 
bipolar I and bipolar II subtypes. Moreover, there was 
no control group of inpatients without serious mental ill-
ness. The analysis of each patient was limited to a single 
index hospitalization and 30 days post-discharge, rather 
than attempting to determine hospital costs or outcomes 
over a longer duration of follow-up. Readmission rates 
in this study may be an underestimate, as these data only 
include admissions to the hospitals in the Premier net-
work, and the likelihood of readmission to hospitals has 
been reported to be as high as 20% elsewhere [22].
Conclusions
In this large, retrospective, administrative database study, 
over 60% of patients with schizophrenia or bipolar disor-
der had at least one cardiometabolic comorbidity, and over 
30% had two or more cardiometabolic comorbidities. For 
patients with schizophrenia, increasing cardiometabolic 
comorbidity burden had a significant impact on cost of 
index hospitalization, and 30-day readmission rates. For 
patients with bipolar disorder, increasing cardiometabolic 
comorbidity burden had a significant impact on length of 
stay, hospital mortality rates, cost of index hospitalization, 
and 30-day readmission rates. These results further under-
score the need for improved detection and management of 
cardiometabolic risk factors in patients with schizophrenia 
or bipolar disorder across different clinical care settings. 
Further research is needed to better understand the long-
term consequences of cardiometabolic comorbidity bur-
den on patients with schizophrenia or bipolar disorder.
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